myleran- busulfan tablet, film coated
aspen global inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan 2 mg - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.
myleran tablet
glaxowellcome - busulfan - tablet - 2 mg
myleran tablet
aspen pharma trading limited (aptl), ireland - busulfan - tablet - 2 mg
myleran tablet
aspen - busulfan - tablet - 2 mg
myleran- busulfan tablet, film coated
woodward pharma services llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.
myleran- busulfan tablet, film coated
waylis therapeutics llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.
myleran tablets 2mg
aspen medical products malaysia sdn bhd - busulphan -
myleran 2mg f.c.tab.
glaxo smithkline-egypt - coated tablet - 2 mg
leukeran tablet
aspen pharmacare canada inc. - chlorambucil - tablet - 2mg - chlorambucil 2mg - antineoplastic agents
lanvis tioguanine 40mg tablet bottle
aspen pharmacare australia pty ltd - tioguanine, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; magnesium stearate; potato starch; acacia - indications as at 10 october 2005: acute myeloblastic leukaemia. less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. although superior results are generally obtained with busulphan (myleran) in the treatment of chronic granulocytic leukaemia. lanvis may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. a degree of cross resistance exists between lanvis (thioguanine) and puri-nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. unlike mercaptopurine the detoxification of lanvis is not dependent on xanthine oxidase, hence therapy with lanvis is not affected by the xanthine oxidase inhibitor, allopurinol (zyloprim). recent evidence suggests that lanvis is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. not effective for the treatment of chronic lymphocytic l